Trexquant Investment’s Neurocrine Biosciences NBIX Stock Holding History

Trexquant Investment’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$24.1M	Buy	183,310 +46,124	+34%	+$6.12M	0.17%	119
2025 Q4	$19.5M	Buy	137,186 +105,441	+332%	+$15.3M	0.17%	115
2025 Q3	$4.46M	Buy	+31,745	New	+$4.3M	0.05%	594
2025 Q2	–	Sell	-40,542	Closed	-$4.48M	–	1762
2025 Q1	$4.48M	Sell	40,542 -15,644	-28%	-$1.98M	0.05%	550
2024 Q4	$7.67M	Sell	56,186 -43,163	-43%	-$5.34M	0.09%	364
2024 Q3	$11.4M	Buy	+99,349	New	+$13.6M	0.14%	205
2024 Q2	–	Sell	-37,918	Closed	-$5.23M	–	1744
2024 Q1	$5.23M	Sell	37,918 -50,242	-57%	-$6.86M	0.1%	285
2023 Q4	$11.6M	Buy	88,160 +82,139	+1,364%	+$9.45M	0.26%	82
2023 Q3	$677K	Buy	+6,021	New	+$634K	0.02%	893
2023 Q2	–	Sell	-58,769	Closed	-$5.95M	–	1668
2023 Q1	$5.95M	Buy	58,769 +3,022	+5%	+$314K	0.16%	159
2022 Q4	$6.66M	Buy	55,747 +49,911	+855%	+$5.85M	0.19%	140
2022 Q3	$620K	Buy	+5,836	New	+$592K	0.02%	725
2022 Q1	–	Sell	-24,681	Closed	-$2.1M	–	1608
2021 Q4	$2.1M	Buy	+24,681	New	+$2.27M	0.13%	200
2021 Q3	–	Sell	-8,294	Closed	-$807K	–	1364
2021 Q2	$807K	Buy	+8,294	New	+$795K	0.07%	360
2021 Q1	–	Sell	-7,283	Closed	-$698K	–	1347
2020 Q4	$698K	Sell	7,283 -19,462	-73%	-$1.88M	0.07%	351
2020 Q3	$2.57M	Buy	+26,745	New	+$3.09M	0.17%	168
2020 Q1	–	Sell	-50,763	Closed	-$5.46M	–	1315
2019 Q4	$5.46M	Buy	+50,763	New	+$5.31M	0.32%	90
2019 Q3	–	Sell	-17,656	Closed	-$1.49M	–	1028
2019 Q2	$1.49M	Sell	17,656 -3,789	-18%	-$311K	0.13%	229
2019 Q1	$1.89M	Buy	+21,445	New	+$1.79M	0.13%	226
2018 Q4	–	Sell	-16,980	Closed	-$2.09M	–	1215
2018 Q3	$2.09M	Buy	+16,980	New	+$1.93M	0.16%	193
2018 Q2	–	Sell	-31,120	Closed	-$2.58M	–	1098
2018 Q1	$2.58M	Buy	31,120 +28,115	+936%	+$2.37M	0.18%	170
2017 Q4	$233K	Sell	3,005 -1,014	-25%	-$69.2K	0.03%	862
2017 Q3	$246K	Buy	+4,019	New	+$212K	0.06%	538
2017 Q1	–	Sell	-40,116	Closed	-$1.55M	–	1234
2016 Q4	$1.55M	Buy	+40,116	New	+$1.82M	0.25%	90
2016 Q1	–	Sell	-25,014	Closed	-$1.42M	–	1083
2015 Q4	$1.42M	Sell	25,014 -22,686	-48%	-$1.15M	0.12%	269
2015 Q3	$1.9M	Buy	47,700 +4,000	+9%	+$193K	0.16%	171
2015 Q2	$2.09M	Buy	+43,700	New	+$1.85M	0.23%	77
2015 Q1	–	Sell	-25,622	Closed	-$572K	–	1108
2014 Q4	$572K	Buy	+25,622	New	+$485K	0.1%	402

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Trexquant Investment's NBIX Position: Q1 2026 in Review

Trexquant Investment increased its Neurocrine Biosciences (NBIX) stake by 34% in Q1 2026, buying an estimated $6.12M and bringing the position to 183,310 shares worth $24.1M. The position accounts for 0.17% of the portfolio, ranked #119.

Trexquant Investment first reported a position in NBIX in Q4 2014 and has held it in 28 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

Trexquant Investment held 183,310 shares of Neurocrine Biosciences worth $24.1M as of Q1 2026.
Trexquant Investment bought 46,124 Neurocrine Biosciences shares in Q1 2026, an estimated $6.12M.
Neurocrine Biosciences made up 0.17% of Trexquant Investment's portfolio in Q1 2026, its #119 holding.
Trexquant Investment first reported a position in Neurocrine Biosciences in Q4 2014 and has held it in 28 quarters since.
694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Trexquant Investment's 13F filing for Q1 2026, filed 15 May 2026.